Cautious Optimism and Considerations for Health Providers and Patients: Oral Antiviral for Early Treatment of High-Risk Patients and Vaccines for Prevention of COVID-19.

Among 2085 randomized subjects, the primary outcome occurred in 0.8% of 1039 who received the active drug (1 death) and 7.8% of 1046 given placebo (10 deaths), a highly significant 88% reduction. 1 The following day, the FDA issued another EUA for a novel viral RNA polymerase inhibitor, molnupiravir (Merck/Ridgeback Biotherapeutics).

also in 132,142 other papers